drugset
drugset / Trial / NCT06590896

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

NCT06590896 ↗

Phase 2 Recruiting 100 enrolled Ono Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures

Timeline

Start
2022-11-04
Primary completion
2027-01-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenobamate Small molecule — Oral

Indications

focal epilepsy